TYBR Health develops extracellular matrix-based products intended to protect healing tissues following surgery, centered on its FDA-cleared B3 GEL® System. B3 GEL® is a flowable extracellular matrix hydrogel designed to conform to complex three-dimensional anatomy and be rapidly applied within existing surgical workflows. Since launch, the system has been used in hand, wrist, shoulder, foot and ankle, and sports medicine procedures, with early adoption by surgeons seeking straightforward intraoperative tissue protection. The company says the product adheres where applied and forms a protective barrier through the healing window. TYBR Health plans to use the Series A proceeds to expand commercial access, broaden indications, and run clinical studies evaluating tissue protection during orthopedic surgery. The company is headquartered in Houston, Texas.

Total raised

$30M

Funding rounds

1

Latest round

Series A

Latest activity

Jul 2026